High-sensitivity troponin: where are we now and where do we go from here?

被引：0
|
作者：
Korley, Frederick K. [1 ]
Jaffe, Allan S. [2 ,3 ,4 ]
机构：
[1] Johns Hopkins Univ, Dept Emergency Med, Sch Med, Baltimore, MD 21209 USA
[2] Mayo Clin & Mayo Grad Sch Med, Cardiovasc Div, Rochester, MN USA
[3] Mayo Clin & Mayo Grad Sch Med, Div Core Clin Lab Serv, Dept Med, Rochester, MN USA
[4] Mayo Clin & Mayo Grad Sch Med, Dept Lab Med & Pathol, Rochester, MN USA
来源：
BIOMARKERS IN MEDICINE | 2014年 / 8卷 / 08期
关键词：
acute coronary syndrome; cardiovascular disease prevention; high-sensitivity troponin; review; structural heart disease; troponin; ACUTE CORONARY SYNDROME; ELEVATION MYOCARDIAL-INFARCTION; CHEST-PAIN SYMPTOMS; HEART-FAILURE RISK; CARDIAC TROPONIN; EARLY-DIAGNOSIS; ATRIAL-FIBRILLATION; PROGNOSTIC VALUE; ATHEROSCLEROSIS RISK; RELATIVE CHANGES;
D O I：
10.2217/BMM.14.54
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
High-sensitivity troponin (hsTn) assays are used clinically in most parts of the world and are expected to be approved by the US FDA for clinical use in the USA soon. Clinical use of hsTn leads to improvements in the detection of myocardial injury, shorter time to ruling out acute myocardial infarction, improved risk-stratification of patients with heart failure and atrial fibrillation among others. HsTn may also guide strategies for primary and secondary prevention of cardiovascular disease. However, unmet challenges remain, including distinguishing between acute and chronic hsTn elevations, distinguishing between type 1 and type 2 acute myocardial infarction and determining whether to use gender-neutral or gender-specific reference values.
引用
收藏
页码：1021 / 1032
页数：12
相关论文
共 50 条
  • [1] Where are we now? Where do we go from here?
    Poppe, Krijn J.
    Termeer, Catherine J. A. M.
    Slingerland, Maja
    [J]. TRANSITIONS TOWARDS SUSTAINABLE AGRICULTURE AND FOOD CHAINS IN PERI-URBAN AREAS, 2009, : 359 - 373
  • [2] Multimedia: Where are we now and where do we go from here?
    Kieley, JM
    [J]. BEHAVIOR RESEARCH METHODS INSTRUMENTS & COMPUTERS, 1996, 28 (02): : 300 - 304
  • [3] Editorial: Where Are We Now and Where Do We Go From Here
    Manganaro, Gabriele
    [J]. IEEE OPEN JOURNAL OF CIRCUITS AND SYSTEMS, 2022, 3 : 1 - 3
  • [4] Troponin, where do we go from here?
    Jaffe, AS
    [J]. CLINICS IN LABORATORY MEDICINE, 1997, 17 (04) : 737 - +
  • [5] OPTICAL ARCHIVING - WHERE ARE WE NOW AND WHERE DO WE GO FROM HERE
    DAVIS, DL
    [J]. OPTICAL INFORMATION SYSTEMS, 1987, 7 (01): : 66 - 71
  • [6] Resistant Hypertension: Where are We Now and Where Do We Go from Here?
    Pathan, Mansur K.
    Cohen, Debbie L.
    [J]. INTEGRATED BLOOD PRESSURE CONTROL, 2020, 13 : 83 - 93
  • [7] WHERE DO WE GO FROM HERE BOYS, WHERE DO WE GO FROM HERE
    WATTERS, D
    [J]. SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 1984, 33 : 567 - 568
  • [8] Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
    Lippi, Giuseppe
    Plebani, Mario
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (12) : 2075 - 2080
  • [9] Now what? Where do we go from here?
    Mehta, Noshir
    [J]. CRANIO-THE JOURNAL OF CRANIOMANDIBULAR & SLEEP PRACTICE, 2021, 39 (01): : 4 - 4
  • [10] Meaningful Use: How Did We Do, Where Are We Now, Where Do We Go from Here?
    Lim, Michele C.
    Chiang, Michael F.
    Boland, Michael V.
    McCannel, Colin A.
    Wedemeyer, Linda
    Epley, K. David
    Silverstone, David E.
    Saini, Arvind
    Lum, Flora
    [J]. OPHTHALMOLOGY, 2014, 121 (09) : 1667 - 1669
12345